145 related articles for article (PubMed ID: 12810202)
21. Goserelin and locally advanced prostate cancer: new indication. Pros and cons.
Prescrire Int; 2000 Jun; 9(47):75-6. PubMed ID: 11010743
[TBL] [Abstract][Full Text] [Related]
22. Androgenic suppression combined with radiotherapy for the treatment of prostate adenocarcinoma: a systematic review.
Sasse AD; Sasse E; Carvalho AM; Macedo LT
BMC Cancer; 2012 Feb; 12():54. PubMed ID: 22299707
[TBL] [Abstract][Full Text] [Related]
23. Goserelin acetate in combination with radiotherapy for prostate cancer.
Roach M; Izaguirre A
Expert Opin Pharmacother; 2007 Feb; 8(2):257-64. PubMed ID: 17257094
[TBL] [Abstract][Full Text] [Related]
24. Acceptability of short term neo-adjuvant androgen deprivation in patients with locally advanced prostate cancer.
Lamb DS; Denham JW; Mameghan H; Joseph D; Turner S; Matthews J; Franklin I; Atkinson C; North J; Poulsen M; Kovacev O; Robertson R; Francis L; Christie D; Spry NA; Tai KH; Wynne C; Duchesne G
Radiother Oncol; 2003 Sep; 68(3):255-67. PubMed ID: 13129633
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC ('Arimidex', Tamoxifen Alone or in Combination) trial.
Locker GY; Mansel R; Cella D; Dobrez D; Sorensen S; Gandhi SK;
Breast Cancer Res Treat; 2007 Dec; 106(2):229-38. PubMed ID: 17245540
[TBL] [Abstract][Full Text] [Related]
26. Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31.
Souhami L; Bae K; Pilepich M; Sandler H
J Clin Oncol; 2009 May; 27(13):2137-43. PubMed ID: 19307511
[TBL] [Abstract][Full Text] [Related]
27. [Adjuvant or therapeutic androgen suppression in locoregional advanced prostatic carcinoma (RTOG 85-31)].
Hinkelbein W
Strahlenther Onkol; 1998 Jul; 174(7):385-6. PubMed ID: 9689964
[No Abstract] [Full Text] [Related]
28. A cost effectiveness analysis of goserelin compared with danazol as endometrial thinning agents.
Sculpher M; Thompson E; Brown J; Garry R
BJOG; 2000 Mar; 107(3):340-6. PubMed ID: 10740330
[TBL] [Abstract][Full Text] [Related]
29. Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma: a complication-adjusted number-needed-to-treat analysis.
Jani AB; Kao J; Hellman S
Cancer; 2003 Dec; 98(11):2351-61. PubMed ID: 14635069
[TBL] [Abstract][Full Text] [Related]
30. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer.
Pisansky TM
Urology; 2003 Dec; 62 Suppl 1():36-45. PubMed ID: 14747040
[TBL] [Abstract][Full Text] [Related]
31. Treatment of prostate cancer with goserelin and radiotherapy.
Vicini FA; Kini VR; Martinez AA
N Engl J Med; 1997 Dec; 337(23):1693-4. PubMed ID: 9411236
[No Abstract] [Full Text] [Related]
32. [Combination of external irradiation and androgen suppression for prostate cancer: facts and questions].
Bolla M; Fourneret P; Beneyton V; Tessier A; Jover F; Verry C
Cancer Radiother; 2010 Oct; 14(6-7):510-4. PubMed ID: 20728391
[TBL] [Abstract][Full Text] [Related]
33. [Prostate cancer: has local radiation treatment had an impact on survival?].
Chauvet B; Alfonsi M; de Rauglaudre G; Reboul F
Cancer Radiother; 2002 May; 6(3):141-6. PubMed ID: 12116838
[TBL] [Abstract][Full Text] [Related]
34. RTOG study shows improved survival for prostate cancer patients given adjuvant goserelin.
Oncology (Williston Park); 2005 Aug; 19(9):1142. PubMed ID: 16402596
[No Abstract] [Full Text] [Related]
35. Cost-effectiveness analysis of degarelix for advanced hormone-dependent prostate cancer.
Lu L; Peters J; Roome C; Stein K
BJU Int; 2012 Apr; 109(8):1183-92. PubMed ID: 21883830
[TBL] [Abstract][Full Text] [Related]
36. [Combination of radiotherapy and hormonotherapy in locally advanced cancers of the prostate].
Bolla M
Cancer Radiother; 1997; 1(5):439-42. PubMed ID: 9587374
[TBL] [Abstract][Full Text] [Related]
37. Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31. Radiation Therapy Oncology Group.
Corn BW; Winter K; Pilepich MV
Urology; 1999 Sep; 54(3):495-502. PubMed ID: 10475361
[TBL] [Abstract][Full Text] [Related]
38. Response of cerebral metastasis secondary to prostate cancer to primary androgen suppression.
Bhuva NJ; Ward D; Hughes R
BMJ Case Rep; 2010 Nov; 2010():. PubMed ID: 22789555
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant androgen withdrawal prior to external radiotherapy for locally advanced adenocarcinoma of the prostate.
Hara I; Miyake H; Yamada Y; Takechi Y; Hara S; Gotoh A; Fujisawa M; Okada H; Arakawa S; Soejima T; Sugimura K; Kamidono S
Int J Urol; 2002 Jun; 9(6):322-8; discussion 328. PubMed ID: 12269247
[TBL] [Abstract][Full Text] [Related]
40. [Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin].
Chauvet B
Cancer Radiother; 1998; 2(3):312. PubMed ID: 9749132
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
